as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹2,117.7
Change
+6.7 (0.32%)
Open
₹2,125.0
Prev. Close
₹2,111.0
Day High
₹2,135.6
Day Low
₹2,105.0
Volume Analysis
Traded
8,603
Delivered
4,092
Delivery %
47.56%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (29.5%)
- •Strong operating margin (21.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (29.7%)
- •Strong 3-year revenue growth (16.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,164.46 | ₹2,150.03 | ₹2,133.86 | ₹2,119.43 | ₹2,103.26 | ₹2,088.83 | ₹2,072.66 |
| Fibonacci | ₹2,150.03 | ₹2,138.34 | ₹2,131.12 | ₹2,119.43 | ₹2,107.74 | ₹2,100.52 | ₹2,088.83 |
| Camarilla | ₹2,126.12 | ₹2,123.31 | ₹2,120.51 | ₹2,119.43 | ₹2,114.9 | ₹2,112.09 | ₹2,109.29 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+51.01%
1 Week
-4.3%
1 Month
+1.84%
3 Months
+7.64%
6 Months
+37.42%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹288.26
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
25.14%
Net margin 13.46% × asset turnover 1.16x × equity multiplier 1.61x
Company Overview
Sector
Healthcare
Market Cap
₹13,219 Cr
P/E (TTM)
62.3
ROE
29.5%
Book Value
₹122.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Corona Remedies Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (2/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (29.5%); strong operating margin (21.0%). Strong 3-year EPS growth (29.7%).
TopFund Score — Fundamentals Quality
74/100 — GoodData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
- +Company has been maintaining a healthy dividend payout of 29.3%
- −Stock is trading at 17.7 times its book value
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Sepia Investments, Sage Investment Trust and Anchor Partners sold 2.63 million shares on 10 September 2026.
Corona Remedies clarifies share volume movement is market-driven, with no undisclosed price-sensitive information.
Exchange has sought clarification from Corona Remedies Ltd on September 10, 2026, with reference to Movement in Volume.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses + | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21.0% | 23.0% | 18.0% | 20.0% | 22.0% | 24.0% | 18.0% | 22.0% |
| Other Income + | 2 | 1 | 2 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 44 | 61 | 70 | 55 | 55 | 80 |
| Tax % | 25.0% | 23.0% | 28.0% | 24.0% | 25.0% | 25.0% | 17.0% | 25.0% |
| Net Profit + | 43 | 45 | 32 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7 | 7 | 5 | 8 | 9 | 7 | 7 | 10 |
| Raw PDF | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Expenses + | 756 | 859 | 956 | 1,109 | 1,162 |
| Operating Profit | 128 | 156 | 241 | 294 | 317 |
| OPM % | 14.0% | 15.0% | 20.0% | 21.0% | 21.0% |
| Other Income + | 7 | 5 | 6 | -9 | -7 |
| Interest | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 20 | 28 | 37 | 38 | 42 |
| Profit before tax | 111 | 118 | 199 | 240 | 260 |
| Tax % | 23.0% | 24.0% | 25.0% | 23.0% | — |
| Net Profit + | 85 | 90 | 149 | 185 | 199 |
| EPS in Rs | 14 | 15 | 24 | 30 | 33 |
| Dividend Payout % | 20.0% | 25.0% | 30.0% | 33.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Reserves | 347 | 419 | 545 | 686 |
| Borrowings + | 28 | 159 | 86 | 165 |
| Other Liabilities + | 159 | 191 | 237 | 293 |
| Total Liabilities | 595 | 831 | 930 | 1,205 |
| Fixed Assets + | 185 | 384 | 370 | 554 |
| CWIP | 65 | 121 | 186 | 143 |
| Investments | 32 | 26 | 26 | 26 |
| Other Assets + | 314 | 301 | 348 | 482 |
| Total Assets | 595 | 831 | 930 | 1,205 |
| Equity Capital | 61 | 61 | 61 | 61 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 103 | 157 | 190 | 229 |
| Cash from Investing Activity + | -50 | -267 | -84 | -256 |
| Cash from Financing Activity + | -45 | 99 | -107 | 25 |
| Net Cash Flow | 8 | -11 | 0 | -1 |
| CFO/OP | 100 | 112 | 97 | 95 |
| Free Cash Flow | 9 | -129 | 99 | 56 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Public | 22.41% | 21.75% | 14.47% |
| Promoters | 69.0% | 69.0% | 69.0% |
| FII | 1.84% | 2.25% | 3.63% |
| DII | 6.77% | 7.02% | 12.9% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Corona Remedies Limited (this stock) | 13,219 | 62.3 | 17.73 | 29.5% |
| Sudeep Pharma Limited | 13,157 | 72.0 | 14.9 | 25.2% |
| Akums Drugs And Pharma L | 12,869 | 42.2 | 3.88 | 8.45% |
| Rainbow Childrens Med Ltd | 13,957 | 48.7 | 8.48 | 15.9% |
| Park Medi World Limited | 12,368 | 44.5 | 6.11 | 16.8% |
| Indegene Limited | 14,319 | 34.4 | 4.57 | 14.4% |
| Metropolis Healthcare Ltd | 12,086 | 58.1 | 7.99 | 13.6% |
Which Mutual Funds Hold Corona Remedies Limited?
Frequently Asked Questions about Corona Remedies Limited
Corona Remedies Limited (CORONA) closed at ₹2,117.7 on NSE on 25 September 2026, up 6.7 (0.32%) from the previous close.
Corona Remedies Limited trades on the NSE (National Stock Exchange of India) under the symbol CORONA.
Corona Remedies Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 62.3.
Corona Remedies Limited has a dividend yield of 0.46%.
Corona Remedies Limited's 52-week high is ₹2,292.0 and its 52-week low is ₹1,337.0.
Corona Remedies Limited has a market capitalisation of ₹13,219 crore.
Corona Remedies Limited has a TopFund Quality Score of 74/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Corona Remedies Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.